Idiotype Vaccination Using Dendritic Cells after Autologous Peripheral Blood Progenitor Cell Transplantation for Multiple Myeloma

Biology of Blood and Marrow Transplantation

Volumn 6, Issue 6, 2000, Pages 621-627

  Liso, Arcangelo ^a   Stockerl Goldstein, Keith E ^a   Auffermann Gretzinger, Susanne ^a   Benike, Claudia J ^b   Reichardt, Volker ^a   Van Beckhoven, Adrienne ^a   Rajapaksa, Ranjani ^a   Engleman, Edgar G ^b   Blume, Karl G ^a   Levy, Ronald ^a,c  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dendritic cells; Idiotype; Multiple myeloma; Transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN IDIOTYPE;

ADULT; ARTICLE; AUTOTRANSPLANTATION; CLINICAL TRIAL; DENDRITIC CELL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; TRANSPLANTATION; VACCINATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DENDRITIC CELLS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN IDIOTYPES; IMMUNOTHERAPY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; TRANSPLANTATION, AUTOLOGOUS; VACCINATION;

EID: 0033655655     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(00)70027-9     Document Type: Article

References (33)

1. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91-97.
2. Reichardt VL, Okada CY, Stockerl-Goldstein KE, Bogen B, Levy R. Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma. Biol Blood Marrow Transplant. 1997;3:157-163.
3. Lynch RG, Graff RJ, Sirisinha S, Simms ES, Eisen HN. Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci U S A. 1972;69:1540-1544.
4. Sirisinha S, Eisen HN. Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins. Proc Natl Acad Sci U S A. 1971;68:3130-3135.
5. King CA, Spellerberg MB, Zhu D, et al. DNA vaccines with single-chain FV fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med. 1998;4:1281-1286.
6. Bogen B, Malissen B, Haas W. Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class ii molecules. Eur J Immunol. 1986;16:1373-1378.
7. + T cells confer idiotype-specific tumor resistance in the absence of antibodies. Eur J Immunol. 1995;25:3079-3086.
8. + T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci U S A. 1994;91:5700-5704.
9. Bendandi M, Gocke CD, Kobrin CB, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med. 1999;5:1171-1177.
10. Cao W, Myers-Powell BA, Braciale TJ. Recognition of an immunoglobulin VH epitope by influenza virus-specific class I major histocompatibility complex-restricted cytolytic T lymphocytes. J Exp Med. 1994;179:195-202.
11. Yamamoto H, Araki K, Bitoh S, et al. Cytotoxic T lymphocyte clone recognizing self idiotype: its regulatory role in antibody production. Eur J Immunol. 1987;17:719-722.
12. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med. 1999;50:507-529.
13. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med. 1995;1:1297-1302.
14. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996;2:52-58.
15. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328-332.
16. Massaia M, Borrione P, Battaglio S, et al. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood. 1999;94:673-683.
17. Osterborg A, Yi Q, Henriksson L, et al. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8-and CD4-specific T-cell responses. Blood. 1998;91:2459-2466.
18. Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: a feasibility study. Blood. 1999;93:2411-2419.
19. Kwak LW, Taub DD, Duffey PL, et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet. 1995;345:1016-1020.
20. Duhamel RC, Schur PH, Brendel K, Meezan E. Ph gradient elution of human IgG1, IgG2 and IgG4 from protein A-sepharose. J Immunol Methods. 1979;31:211-217.
21. Kwak LW, Campbell MJ, Czerwinski DK, et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med. 1992;327:1209-1215.
22. Timmerman JM, Levy R. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. J Immunol. 2000;164:4797-4803.
23. Govindarajan R, Jagannath S, Flick JT, et al. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol. 1996;95:349-353.
24. + T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur J Immunol. 1996;26:2671-2679.
25. Flamand V, Sornasse T, Thielemans K, et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol. 1994;24:605-610.
26. Kwak LW, Jagannath S, Siegel D, Munshi NC, Barlogie B. T cell responses elicited by immunization of multiple myeloma patients with idiotypic M-protein plus GM-CSF in remission after autologous transplantation. Blood. 1997;90:579a.
27. Cull G, Durrant L, Stainer C, Haynes A, Russell N. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma. Br J Haematol. 1999;107:648-655.
28. MacKenzie MPM, Wun T, et al. Efficacy of idiotype pulsed autologous dendritic cells for treatment of advanced refractory multiple myeloma. Blood. 1999;94:122a.
29. Romani N, Reider D, Heuer M, et al. Generation of mature dendritic cells from human blood: an improved method with special regard to clinical applicability. J Immunol Methods. 1996;196:137-151.
30. + dendritic cells. Proc Natl Acad Sci U S A. 1996;93:2588-2592.
31. Tarte K, Lu ZY, Fiol G, et al. Generation of virtually pure and potentially proliferating dendritic cells from non-CD34 apheresis cells from patients with multiple myeloma. Blood. 1997;90: 3482-3495.
32. Wen YJ, Ling M, Bailey-Wood R, Lim SH. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin Cancer Res. 1998;4:957-962.
33. Munshi NCDR, Siegal D, et al. Preliminary report of clinical efficacy of patient specific vaccination using purified idiotype protein in myeloma. Blood. 1999;94:704a.